ERBB2 and breast cancer: Here, ARID1B mRNA expression was associated with poor prognosis in HER2-riched breast cancers and lymph node-positive patients, ARID4B mRNA expression, which was higher in breast cancer tissues, was interrelated with unfavorable prognosis in all breast cancer patients.